Ibi Inv House (IBI) AI Stock Analysis

• Market Cap: ₪5.08B
• Dividend Yield: 3.92%
• Average Volume (3M): 16.58K
• Price to Earnings (P/E): 33.6
• Beta (1Y): 0.88
• Revenue Growth: 46.14%
• EPS Growth: -17.83%
• Country: IL
• Employees: 937
• Sector: Financial
• Sector Strength: 70
• Industry: Financial - Conglomerates
• EPS (TTM): 333.30
• Shares Outstanding: 14,072,274
• 10 Day Avg. Volume: 11,015
• 30 Day Avg. Volume: 16,583
• PEG Ratio: 1.76
• Price to Book (P/B): 2.31
• Price to Sales (P/S): 2.00
• P/FCF Ratio: 9.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: 40,432.00 ▲(36.64% Upside)

Ibi Inv House's strong financial performance and positive technical indicators are the primary drivers of its overall stock score. While the valuation suggests the stock may be expensive, the solid dividend yield offers some compensation. The lack of earnings call data and corporate events does not impact the score due to their exclusion.

Positive Factors

Revenue & Profitability

Sustained double-digit TTM revenue growth combined with very high gross and healthy net margins indicates a scalable, fee-driven business with strong pricing power and efficient cost structure. These characteristics support durable cash generation and resilience across cycles.

Free Cash Flow Strength

Robust FCF growth and a high FCF-to-net-income ratio demonstrate strong conversion of earnings into cash. This improves financial flexibility to fund investments, pay dividends, and weather downturns without heavy reliance on external financing, supporting long-term stability.

Balance Sheet Health

Moderate leverage, a solid equity base and mid-teens ROE point to prudent capital allocation and capacity to pursue growth. Manageable debt levels preserve strategic optionality and reduce solvency risk, strengthening the company's ability to fund investments and withstand shocks.

Negative Factors

Earnings Decline

Negative EPS growth indicates recent pressure on reported earnings despite revenue gains, suggesting margin compression, non-recurring items, or timing differences. Persistent EPS decline can undermine returns to shareholders and signals potential issues in converting revenue into sustainable profits.

Earnings Quality / Cash Conversion

A low operating cash flow to net income ratio implies earnings are not fully supported by cash from operations, raising questions about quality of reported profits. Over time weak cash conversion can constrain reinvestment, increase financing needs, and amplify vulnerability to economic stress.

Performance Fee & Exit Dependence

Reliance on performance fees and exit-driven gains creates revenue cyclicality tied to market conditions and deal activity. Such dependency reduces predictability of income streams over the medium term and can amplify earnings volatility during periods of weak exit markets or lower realized returns.

Ibi Inv House Business Overview & Revenue Model

Company Description

Ibi Inv House (IBI) is a diversified investment firm specializing in asset management, private equity, and venture capital. The company operates across various sectors, including technology, healthcare, real estate, and renewable energy, providing a comprehensive range of financial services. IBI focuses on identifying high-potential investment opportunities and offers tailored financial solutions to both institutional and retail clients, including fund management, advisory services, and wealth management.

How the Company Makes Money

Ibi Inv House generates revenue primarily through management fees charged on the assets under management (AUM) in its various investment funds. Additionally, the company earns performance fees based on the profits generated from its investments, particularly in private equity and venture capital. Key revenue streams also include advisory fees from corporate clients seeking strategic insights and investment guidance. IBI has established significant partnerships with financial institutions and other investment firms, enhancing its market reach and investment capabilities, which contribute to its overall earnings. Furthermore, IBI capitalizes on investment exit strategies such as IPOs and mergers and acquisitions, which provide substantial returns and boost its revenue.

Ibi Inv House Financial Statement Overview

Summary

Ibi Inv House demonstrates strong financial performance with impressive revenue growth, high profitability margins, and robust cash flow generation. The balance sheet is well-managed with moderate leverage and a solid equity base, reflecting a well-rounded performance.

Income Statement

Ibi Inv House demonstrates strong revenue growth with a 23.26% increase in TTM, supported by high gross and net profit margins of 95.99% and 23.57%, respectively. The EBIT and EBITDA margins are also robust at 54.86% and 66.30%, indicating efficient operational management. The consistent revenue growth trajectory and high profitability margins reflect a solid financial performance.

Balance Sheet

The company's balance sheet is stable with a moderate debt-to-equity ratio of 0.35, suggesting manageable leverage. The return on equity (ROE) is healthy at 15.58%, indicating effective use of equity to generate profits. The equity ratio stands at a solid 42.67%, reflecting a strong equity base relative to total assets. Overall, the balance sheet shows a balanced approach to growth and risk management.

Cash Flow

Ibi Inv House exhibits a strong free cash flow growth rate of 39.42% in TTM, highlighting improved cash generation capabilities. The operating cash flow to net income ratio is 0.34, and the free cash flow to net income ratio is 0.78, indicating efficient conversion of earnings into cash. The positive cash flow trends support the company's financial flexibility and ability to fund operations and investments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	693.61M	1.04B	791.55M	660.61M	548.65M	435.79M
Gross Profit	671.10M	696.21M	511.24M	417.09M	357.00M	279.51M
EBITDA	407.72M	368.28M	281.08M	212.29M	227.69M	150.50M
Net Income	146.12M	178.14M	156.46M	90.76M	139.58M	81.94M
Balance Sheet
Total Assets	2.09B	1.85B	1.27B	1.08B	1.13B	1.02B
Cash, Cash Equivalents and Short-Term Investments	603.89M	519.23M	453.00M	246.53M	547.09M	530.66M
Total Debt	303.18M	243.90M	201.26M	154.42M	334.90M	197.25M
Total Liabilities	972.93M	750.27M	539.07M	399.48M	521.39M	469.80M
Stockholders Equity	891.39M	899.76M	686.62M	640.44M	575.47M	522.10M
Cash Flow
Free Cash Flow	209.21M	218.35M	207.56M	45.23M	190.60M	68.70M
Operating Cash Flow	244.07M	249.28M	269.65M	61.11M	197.55M	79.24M
Investing Cash Flow	-117.41M	-97.88M	-269.38M	-44.08M	36.90M	-83.84M
Financing Cash Flow	-70.00M	-141.00K	-37.48M	-80.76M	-196.36M	24.85M

Ibi Inv House Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 29590.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:IBI, the sentiment is Positive. The current price of 29590 is below the 20-day moving average (MA) of 34239.00, below the 50-day MA of 31425.92, and above the 200-day MA of 25434.81, indicating a bullish trend. The MACD of 1203.33 indicates Positive momentum. The RSI at 74.36 is Negative, neither overbought nor oversold. The STOCH value of 77.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:IBI.

Ibi Inv House Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IBI	74 Outperform	₪5.08B	33.60	―	3.92%	46.14%	-17.83%
ATRY	73 Outperform	₪1.25B	11.71	―	6.06%	687.69%	21.73%
Sector *	68 Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
IDIN	60 Neutral	₪3.66B	10.63	―	5.98%	19.48%	53.61%